R-Tech Ueno, Sucampo, Par Pharmaceutical ophthalmic news

The companies said that “in limited circumstances” Sucampo and R-Tech would grant Par a license to market a generic version of 0.15% Rescula unoprostone isopropyl prior to the latest expiration date of the patents, which is July 2021. Under such license, Par and Sucampo would split the gross profits of the generic sold until the last of the patents covering Rescula have expired. Par may elect to launch an authorized generic, which Sucampo would supply at a negotiated price. Sucampo said the “limited circumstances would be if another generic could enter the market prior to July 2021.” Par has submitted an ANDA to FDA for its generic version. ...